Biogen Inc. CEO Chris Viehbacher has indicated that a successful trial of Novo Nordisk A/S‘s weight-loss drug could create opportunities for enhanced treatment strategies for Alzheimer’s disease. In a recent interview with Bloomberg News, Viehbacher emphasized that rather than presenting a threat to Biogen’s Alzheimer’s treatment, the trial outcomes could facilitate the combination of therapies, potentially leading to better results.
Viehbacher compared the future of Alzheimer’s treatment to other complex illnesses that often require multiple medications with varied mechanisms of action. He noted that Biogen might consider testing its Alzheimer’s drug, Leqembi, alongside Novo’s semaglutide, contingent on positive trial results. Nonetheless, he also pointed out the lengthy nature of Alzheimer’s studies, which can span several years, adding a layer of complexity to the timing of any collaborative research.
Novo Nordisk is currently conducting clinical trials to evaluate the efficacy of semaglutide, the active ingredient in its diabetes drug Ozempic and weight-loss injection Wegovy, in patients diagnosed with early Alzheimer’s. Preliminary research suggests that semaglutide might have the potential to slow disease progression by reducing inflammation and enhancing vascular health. Results from the company’s late-stage study are anticipated later this year.
Viehbacher acknowledged the link between obesity and Alzheimer’s, noting that excess weight is a recognized risk factor for the disease. However, he described Novo’s approach as a “fairly risky proposition,” given the skepticism from several experts regarding its success.
Recent studies have shown that semaglutide, particularly when used in Wegovy for weight loss, can alleviate symptoms related to heart failure and enhance physical capability in individuals suffering from obesity-related heart failure with preserved ejection fraction (HFpEF), regardless of the presence of type 2 diabetes.
In March 2024, Wegovy received approval from the Food and Drug Administration (FDA) for expanded use, marking a significant advancement in preventive health strategies. This approval aims for a notable reduction in major adverse cardiovascular events, including cardiovascular death, nonfatal heart attacks, and nonfatal strokes.
Additionally, in December 2024, the FDA approved Eli Lilly and Co.‘s weight-loss drug Zepbound for treating sleep apnea, further highlighting the evolving landscape of obesity management and its implications for related health conditions.
As the trials for semaglutide continue and new findings emerge, the collaboration potential between Biogen and Novo Nordisk may pave the way for innovative treatment combinations in the fight against Alzheimer’s disease.
